Zhejiang Yaoyuan Biotechnology

Zhejiang Yaoyuan Biotechnology is a clinical-stage biopharmaceutical company focused on developing innovative peptide drugs for metabolic diseases. Founded by industry veterans, the company utilizes a proprietary technology platform to create long-acting multi-receptor agonists targeting GLP-1, GIP, and Glucagon receptors. Its lead candidate, YY001, is a dual GLP-1/GIP receptor agonist currently in clinical development for obesity and type 2 diabetes. The company's pipeline also includes triple agonists and other peptide-based therapies aimed at addressing unmet needs in NASH and other endocrine disorders. Yaoyuan Biotech is headquartered in Hangzhou, China, and has secured significant backing from prominent venture capital firms.